Tirzepatide Binge Eating Disorder Trial Opens at Johns Hopkins

What is the tirzepatide binge eating disorder trial testing?

The ClinicalTrials.gov record for NCT06847399, sponsored by Johns Hopkins University and listed with a September 9, 2026 date, describes a Phase 2 study in adults who have both obesity and binge-eating disorder. The stated purpose is to assess the efficacy and safety of tirzepatide in that population, and the design is unusual for an incretin study: it includes a placebo arm and a second active comparator arm using lisdexamfetamine dimesylate.

Planned enrollment is 105 participants, and the registry lists recruitment status as open. The record also specifies that every participant, regardless of which arm they are assigned to, will receive guided self-help cognitive behavioral therapy. That means the medication comparison is layered on top of a behavioral treatment rather than replacing it, which is closer to how binge-eating disorder is actually managed in clinical practice.

Tirzepatide is a single molecule that activates both the GIP and GLP-1 receptors. In the United States it is marketed by Eli Lilly as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity. Binge-eating disorder is not an approved indication anywhere, and a Phase 2 trial is an early step toward establishing whether it ever could be.

Why researchers are looking at incretin drugs for binge eating

Binge-eating disorder is defined by recurrent episodes of eating unusually large amounts of food with a sense of loss of control, and it frequently co-occurs with obesity. Because incretin drugs slow gastric emptying and act on brain circuits involved in appetite and reward, clinicians and researchers have hypothesized for several years that they might reduce binge episodes. Until now, most of that discussion has rested on case series, retrospective chart reviews, and patient self-report rather than controlled trials.

A placebo-controlled design is what separates a hypothesis from evidence here, and it matters for a particular reason: in a population with obesity, any drug that produces weight loss will also change eating patterns. Without a placebo arm and a comparator with a different mechanism, it is difficult to tell whether fewer binge episodes reflect something specific about incretin signaling or simply the downstream effect of eating less overall.

Nothing in the registry record reports outcomes, and none should be expected yet. The listing describes what will be measured, not what was found. Readers who see this trial referenced online should treat it as a study that has started, not as a result.

People tracking an existing provider-directed regimen often use a tirzepatide dosage calculator to keep syringe-unit math consistent between vials, which is separate from anything this trial is testing.

AstraZeneca's Phase 3 elecoglipron listing describes a 1,200-participant comparison against oral semaglutide in adults with type 2 diabetes and increased cardiovascular risk.

Why lisdexamfetamine is the third arm

Lisdexamfetamine dimesylate, sold as Vyvanse, is a stimulant prodrug approved in the United States for moderate-to-severe binge-eating disorder in adults, alongside its longer-standing use in ADHD. Including it as a comparator arm sets a meaningful bar: rather than only asking whether tirzepatide beats placebo, the Johns Hopkins design asks how it performs against the drug a prescriber would most plausibly reach for today.

Three-arm designs of this kind are expensive and slow to enroll, which is part of why they are rare in the incretin literature. Most registered GLP-1 and dual-agonist studies compare the drug against placebo or against another incretin. Choosing a stimulant as the active control signals that the investigators are interested in the psychiatric outcome, binge frequency and severity, rather than treating weight change as the whole story.

The registry entry for the tirzepatide binge eating disorder trial does not spell out the primary endpoint in the summary text supplied, so how the investigators weight binge remission against weight and metabolic measures will only become clear from the full protocol or the eventual publication.

Because trials like this one measure tolerability alongside efficacy, side-effect logging is the closest a person outside a study comes to producing the same kind of record for their own clinician.

How this fits tirzepatide's widening research footprint

The Johns Hopkins study arrives in the middle of an unusually broad wave of tirzepatide research that reaches well past diabetes and weight. In the International Journal of Cardiology, Karanxha and colleagues published a prospective real-world cohort study examining an association between tirzepatide and reverse cardiac remodeling and diastolic function in obesity-related heart failure with preserved ejection fraction. In Endocrinology, Diabetes & Metabolism, Hageen and colleagues published a network meta-analysis pooling randomized trials of tirzepatide against dulaglutide in type 2 diabetes, with and without established atherosclerotic cardiovascular disease.

Case reports are accumulating in parallel: three cases of postbariatric hypoglycemia after Roux-en-Y gastric bypass in JCEM Case Reports, a case of refractory diabetes in an adult with Prader-Willi syndrome in Medicine, and a dermatologic case in JAAD Case Reports. Individually these are the weakest form of clinical evidence, describing single patients with no control group, but collectively they show clinicians probing the edges of what the drug does.

There is also a counterweight in the same week's literature. Ampofo and colleagues published a systematic review and meta-analysis in Obesity Science & Practice on malnutrition and metabolic failure during high-potency incretin therapy. The abstract record available does not include the pooled findings, but the existence of a dedicated meta-analysis on nutritional adequacy is a reminder that the questions being asked about these drugs now run in both directions.

If terms like arm, endpoint, and comparator are unfamiliar, our glossary entry on what a protocol is covers the vocabulary used in trial records and in provider-directed plans alike.

Other GLP-1 trial records updated this week

Eli Lilly's SURMOUNT-REAL UK study, registered as NCT07247084, is listed as recruiting with a planned 3,000 participants and a Phase 4 designation. According to the registry, it will evaluate tirzepatide in a real-world setting against standard of care in adults with obesity and no diabetes who have at least one weight-related condition, measuring body weight change and incidence of type 2 diabetes over roughly 260 weeks.

AstraZeneca has opened a Phase 3 trial, NCT07662213, testing an investigational drug called elecoglipron against oral semaglutide in 1,200 adults with type 2 diabetes and elevated cardiovascular risk. Head-to-head Phase 3 trials against an approved incretin are how the next generation of glucose-lowering agents will be judged, and the choice of the oral formulation of semaglutide as comparator rather than the injectable is itself informative.

Two long-running Novo Nordisk semaglutide trials also show updated records: a Phase 3 study in children and adolescents with excess body weight, NCT05726227, with 210 participants over about 132 weeks, and a five-year, 1,500-participant Phase 3 study, NCT03811561, examining the long-term effect of semaglutide on diabetic eye disease in people with type 2 diabetes. Both are listed as active but no longer recruiting.

According to the ClinicalTrials.gov record for NCT06847399, Johns Hopkins University plans to enroll 105 adults and compare tirzepatide against both placebo and lisdexamfetamine dimesylate, with guided self-help cognitive behavioral therapy given to all participants.

What the trial will not answer

A 105-participant Phase 2 study is sized to detect a signal and to characterize tolerability, not to support a label change. Even a clean positive result would need replication in larger Phase 3 trials before any regulator considered binge-eating disorder as an indication for a dual incretin agonist, and that pathway typically takes years. A neutral or negative result would be equally informative and would likely cool the current enthusiasm for off-label use.

The trial also will not settle the mechanistic question. Guided self-help cognitive behavioral therapy in all arms improves the ethics and the realism of the design, but it also means any drug effect is measured on top of an active behavioral treatment, which can compress differences between groups. Interpreting the eventual publication will require reading the endpoints carefully rather than the headline.

The SURMOUNT-REAL UK registry entry lists a 3,000-participant Phase 4 study running about 260 weeks in adults with obesity and no diabetes. the SURMOUNT-REAL UK registry entry.